Zentalis Pharmaceuticals Inc expected to post a loss of 77 cents a share - Earnings Preview

Zentalis Pharmaceuticals

06/05/2024 15:20

* Zentalis Pharmaceuticals Inc  ZNTL.OQ   ZNTL.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 8 (estimated) for the period ending March 31 2024
    * The New York City-based  company is expected to report
revenue
of $13.125 million, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Zentalis Pharmaceuticals
Inc
is for a loss of 77 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $37.00​, above​ its last closing price
of $11.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.94       -0.92      -0.93     Missed  -1.5
 Sep. 30 2023  -0.91       -0.91      -0.79     Beat    13.3
 Jun. 30 2023  -1.02       -1.04      -1.85     Missed  -78.3​
 Mar. 31 2023  -0.98       -1.02      -1.07     Missed  -5
 ​​Dec.        -1.01       -1.06      -0.92     Beat    13.2
 31 2022                                                
 Sep. 30 2022  -1.15       -1.17      -0.96     Beat    17.9​
 Jun. 30 2022  -1.18       -1.19      -1.34     Missed  -13
 Mar. 31 2022  -1.21       -1.21      -1.31     Missed  -7.8
 This summary was machine generated May 6 at 14:20 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)